Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Lin

Showing results (161-170 of 211) with videos related to

Pageof 22
Sort By:
Scientific Data|March 5, 2026
WxC-Bench: A Novel Dataset for Weather and Climate Downstream TasksRajat Shinde, Kumar Ankur, Christopher E Phillips, et al.
Molecular Psychiatry|July 27, 2022
Longitudinal trajectories of cortical development in 22q11.2 copy number variants and typically developing controlsMaria Jalbrzikowski, Amy Lin, Ariana Vajdi, et al.
Pharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.
Annals of Internal Medicine|March 5, 2004
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseStephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, et al.
The New England Journal of Medicine|September 27, 2002
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionMichael W Fried, Mitchell L Shiffman, K Rajender Reddy, et al.
Gastroenterology|July 20, 2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirinMark G Swain, Ming-Yang Lai, Mitchell L Shiffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brainMichelle J Hickey, Colin C Malone, Kate L Erickson, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|September 12, 2013
Depressive symptoms in Chinese-American subjects with cognitive impairmentSteven Z Chao, Brandy R Matthews, Jennifer S Yokoyama, et al.
Journal of Medicinal Chemistry|October 5, 2022
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase InhibitorsRongjun He, Jifeng Wang, Zhi-Hong Yu, et al.
Pageof 22

Showing results (161-170 of 211) with videos related to

Sort By:
Pageof 22
Scientific Data|March 5, 2026
WxC-Bench: A Novel Dataset for Weather and Climate Downstream TasksRajat Shinde, Kumar Ankur, Christopher E Phillips, et al.
Molecular Psychiatry|July 27, 2022
Longitudinal trajectories of cortical development in 22q11.2 copy number variants and typically developing controlsMaria Jalbrzikowski, Amy Lin, Ariana Vajdi, et al.
Pharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.
Annals of Internal Medicine|March 5, 2004
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseStephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, et al.
The New England Journal of Medicine|September 27, 2002
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionMichael W Fried, Mitchell L Shiffman, K Rajender Reddy, et al.
Gastroenterology|July 20, 2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirinMark G Swain, Ming-Yang Lai, Mitchell L Shiffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brainMichelle J Hickey, Colin C Malone, Kate L Erickson, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|September 12, 2013
Depressive symptoms in Chinese-American subjects with cognitive impairmentSteven Z Chao, Brandy R Matthews, Jennifer S Yokoyama, et al.
Journal of Medicinal Chemistry|October 5, 2022
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase InhibitorsRongjun He, Jifeng Wang, Zhi-Hong Yu, et al.
Pageof 22